Division of Cardiology, St Michael's Hospital, University of Toronto, 30 Bond St., 6-050 Queen Wing, Toronto, ON, Canada.
Europace. 2010 May;12(5):618-25. doi: 10.1093/europace/euq073. Epub 2010 Mar 19.
The transvenous implantable cardioverter defibrillator (ICD) has emerged as the primary therapy for patients at high risk of life-threatening ventricular arrhythmias. A high number of ICD recipients will require subsequent adjunctive treatment with antiarrhythmic drugs (AADs). This review provides an overview of potential reasons for AAD initiation, candidates for treatment, current medical options, and possible drug-device interactions.
经静脉植入式心脏复律除颤器（ICD）已成为高危致死性室性心律失常患者的主要治疗手段。许多 ICD 接受者将需要随后使用抗心律失常药物（AAD）进行辅助治疗。本文综述了启动 AAD 的潜在原因、治疗候选者、当前的医学选择以及可能的药物-器械相互作用。
